Company / R&D Expense
Mirum Pharmaceuticals, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$186.2M
FY2025
5-year range
$81.6M / $186.2M
FY2021-FY2025
Trend
+32.4%
vs FY2024
Sector context
#86 of 210
Health Care
What the data says
At $186M, Mirum Pharmaceuticals, Inc.'s r&d expense ranks #86 of 210 in the Health Care sector. Improved from $103M to $186M over the past 2 years.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of +17.9%.
Improved from $103M to $186M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Sector benchmark
#86 of 210 in Health CareTop 41% of 210This company $186.2M Sector average $644.0M
▼
-71.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2025, r&d expense increased 32.4% year-over-year.
- Ranks #86 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.2M | +32.4% |
| FY2024 | $140.6M | +37.1% |
| FY2023 | $102.6M | -21.9% |
| FY2022 | $131.4M | +61.1% |
| FY2021 | $81.6M | +0.0% |
| FY2020 | $81.6M | +89.8% |
| FY2019 | $43.0M | +1744.3% |
| FY2018 | $2.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026